Clinicians and genetic counselors are coming up with triage strategies for cancer cases in which medically actionable germline mutations are suspected.
The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.
UPenn will establish the Coordinating Center for Genetics and Genomics of Alzheimer's Disease in collaboration with five other institutions.
The UPenn-led study proposal calls for editing three genes in autologous T cells with CRISPR and includes preliminary data for on- and off-target editing.
A safety panel is to review a proposal next week to use CRISPR as part of a cancer treatment, Technology Review reports.
A member of the committee issuing a blunt report on the inadequacy of biomarker-based testing speaks about what the next Secretary of HHS needs to do.
The university formed the new venture in collaboration with Blueprint Bio and Emerald Logic in order to discover biomarkers for personalized medicine.
Researchers saw an 'incremental clinical benefit' from analyzing 180 genes in the exomes of hundreds of individuals from families affected by breast or ovarian cancer.
The group compared results of 304 cancer specimens tested by both NGS and one or more single-gene tests, showing almost complete concordance.
The institute will combine expertise from six cancer centers in the US in order to drive research and drug development in cancer immunotherapy.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.